University of California, Irvine |
Mathew Blurton-Jones |
Quest - Discovery Stage Research Projects |
Transplantation of Pluripotent Stem Cell Derived Microglia for the Treatment of Adult-onset Leukoencephalopathy (HDLS/ALSP) |
$214,668 |
University of Southern California |
Justin Ichida |
Quest - Discovery Stage Research Projects |
Development of a SYF2 antisense oligonucleotide (ASO) treatment for ALS |
$222,300 |
University of California, Irvine |
Robert Hunt |
Quest - Discovery Stage Research Projects |
Optimization of a human interneuron cell therapy for traumatic brain injury |
$250,000 |
University of California, Los Angeles |
Stanley Carmichael |
Quest - Discovery Stage Research Projects |
Human-induced pluripotent stem cell-derived glial enriched progenitors to treat white matter stroke and vascular dementia. |
$250,000 |
University of California, San Diego |
Tariq Rana |
Quest - Discovery Stage Research Projects |
Development of COVID-19 Antiviral Therapy Using Human iPSC-Derived Lung Organoids |
$250,000 |
City of Hope, Beckman Research Institute |
Yanhong Shi |
Quest - Discovery Stage Research Projects |
Combating COVID-19 using human PSC-derived NK cells |
$249,998 |
Boston Children's Hospital |
David Williams |
Cure Sickle Cell Initiative Clinical Trial Stage Projects |
Phase 2 Study of Hematopoietic Stem Cell Gene Transfer Inducing Fetal Hemoglobin in Sickle Cell Disease |
$8,333,581 |
University of California, San Francisco |
Steven Deeks |
Clinical Trial Stage Projects |
Anti-HIV duoCAR-T cell therapy for HIV infection |
$8,970,732 |
Rocket Pharmaceuticals, Inc. |
Gayatri Rao |
Clinical Trial Stage Projects |
A Phase I Clinical Trial for a Lentiviral Gene Therapy Targeting the TCIRG1 Gene for Infantile Malignant Osteopetrosis (IMO) |
$3,728,485 |
University of California, Davis |
Diana Farmer |
Clinical Trial Stage Projects |
The CuRe Trial: Cellular Therapy for In Utero Myelomeningocele Repair |
$8,996,474 |
University of California, San Diego |
Dan Kaufman |
Quest - Discovery Stage Research Projects |
Human iPSC-derived chimeric antigen receptor-expressing macrophages for cancer treatment |
$222,200 |
University of California, Los Angeles |
Donald Kohn |
Quest - Discovery Stage Research Projects |
Hematopoietic Stem Cell Gene Therapy for X-linked Agammaglobulinemia |
$219,230 |
Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center |
Eiji Yoshihara |
Quest - Discovery Stage Research Projects |
Dual angiogenic and immunomodulating nanotechnology for subcutaneous stem cell derived islet transplantation for the treatment of diabetes |
$250,000 |
Vitabolus, Inc. |
Aline Betancourt |
Quest - Discovery Stage Research Projects |
The First Orally Delivered Cell Therapy for the Treatment of Inflammatory Bowel Disease |
$249,000 |
University of California, San Diego |
Mark Tuszynski |
Progression Award - Discovery Stage Research Projects |
Simplification of Excipient Solution for Implanting Candidate Human H9-scNSC Cell Line for Spinal Cord Injury |
$180,000 |
Stanford University |
Helen Blau |
Progression Award - Discovery Stage Research Projects |
Stimulating endogenous muscle stem cells to counter muscle wasting |
$237,060 |
University of California, Berkeley |
Kevin Healy |
Progression Award - Discovery Stage Research Projects |
Safety “Clinical Trial” of the Cardiac Liability of COVID19 Polytherapy |
$224,500 |
University of California, Irvine |
Brian Cummings |
Progression Award - Discovery Stage Research Projects |
Human neural stem cell (hNSC) derived exosomes vs CSC14 hNSCs for the treatment of traumatic brain injury (TBI) |
$202,667 |
University of California, San Diego |
Karen Christman |
Discovery Research Projects |
Pro-healing biomaterial for treating lung inflammation associated with COVID-19 |
$221,758 |
University of California, Los Angeles |
Lili Yang |
Discovery Research Projects |
Battling COVID-19 Using Off-The-Shelf HSC-Engineered iNKT Cells |
$250,000 |
Neurona Therapeutics |
Cory Nicholas |
Progression Award - Discovery Stage Research Projects |
Global gene expression profiling of single inhibitory neurons derived from human stem cells |
$202,500 |
University of California, Irvine |
Daniela Bota |
Conference – The 2020 Grantee Meeting |
2020 CIRM Grantee Meeting |
$157,862 |
Sanford Burnham Prebys Medical Discovery Institute |
Evan Snyder |
Discovery Research Projects |
Using hiPSC-derived lung organoids, a clinically-relevant system, to validate & winnow a list of approved drugs that inhibit SARS-CoV-2 cytopathy |
$228,229 |
University of California, San Diego |
Steve Dowdy |
Discovery Research Projects |
Development of Anti-COVID RNAi Therapeutics Using Human iPSC-Derived Alveolar Epithelial Cells |
$150,000 |
Celularity Inc |
Xiaokui Zhang |
Clinical Trial Stage Projects |
A phase I/II study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for the treatment of adults with COVID-19 |
$750,000 |
University of Southern California |
PREET Chaudhary |
Discovery Research Projects |
Chimeric Antigen Receptor Targeting Spike Glycoprotein of SARS-cov2 |
$249,996 |
University of California, Los Angeles |
Song Li |
Discovery Research Projects |
Biomaterial vaccine to enhance the formation of SARS-CoV-2-specific T memory stem cells |
$149,916 |
University of California, Los Angeles |
Vaithilingaraja Arumugaswami |
Therapeutic Translational Research Projects |
COVID-19 Antiviral Therapy to Block Direct Cell Injury and Associated Tissue Damage |
$349,999 |
Stanford University |
Helen Blau |
Discovery Research Projects |
Application of PGE2/BPV, a muscle stem cell targeting therapeutic, to the treatment of COVID-19 associated diaphragm atrophy |
$149,996 |
Stanford University |
Albert Wong |
Discovery Research Projects |
Identifying HLA Class I Restricted Peptides That Induce CD8+ T Cells Against SARS-CoV-2 |
$249,999 |
City of Hope, Beckman Research Institute |
Jianhua Yu |
Discovery Research Projects |
Persistent Off-the-Shelf meACE2-CAR-IL-15 NK Cells Derived from CD34(+) Cord Blood Stem Cells to Prevent and Treat COVID-19 |
$150,000 |
University of California, Los Angeles |
Caroline Kuo |
Progression Award - Discovery Stage Research Projects |
Evaluation of Gene Therapy Approaches for Autosomal Recessive Hyper IgE Syndrome Due to Mutations in DOCK8 |
$234,000 |
Scripps Research Institute |
Stuart Lipton |
Discovery Research Projects |
Repurposing Aminoadamantane Nitrate Compounds to Inhibit SARS-CoV-2 Viral Activity and to Protect the Brain from Viral-Related Damage |
$150,000 |
University of Southern California |
Justin Ichida |
Discovery Research Projects |
Development of a novel PIKFYVE kinase inhibitor for the treatment of COVID-19 |
$150,000 |
University of California, San Francisco |
Michael Matthay |
Clinical Trial Stage Projects |
Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative) |
$701,049 |
ExCellThera Inc. |
Pierre Caudrelier |
Cure Sickle Cell Initiative Clinical Trial Stage Projects |
A Phase 1 Study of ECT-001 Expanded Cord Blood and Myeloablative Regimen with Reduced Toxicity in Patients with Severe Sickle Cell Disease. |
$2,000,000 |
University of California, Los Angeles |
Brigitte Gomperts |
Discovery Research Projects |
Identifying a lead compound for COVID19 using high throughput screening with lung stem cell organoids |
$149,998 |
University of California, Los Angeles |
Gay Crooks |
Discovery Research Projects |
Stem cell-based rapid identification of SARS-CoV-2 T cell epitopes and T cell receptors for therapeutic use |
$126,692 |
City of Hope, Beckman Research Institute |
John Zaia |
Clinical Trial Stage Projects |
Evaluation and Characterization of SARS-CoV-2 Antibody in Convalescent Volunteer Plasma Donors for Potential Therapeutic Use |
$999,999 |
Stanford University |
Hiromitsu Nakauchi |
Progression Award - Discovery Stage Research Projects |
Using metabolic pausing for maintaining stable and high-quality pluripotent stem cells |
$208,422 |
University of California, Davis |
Gerhard Bauer |
Conference - Manage The SPARK Annual Meeting |
The 2020 SPARK Annual Meeting |
$50,000 |
Stanford University |
Rosa Bacchetta |
Late Stage Preclinical Projects |
IND-enabling activities for a Phase 1 Study of Autologous CD4LVFOXP3 T Cells in Subjects with IPEX Syndrome |
$5,002,496 |
jCyte, Inc |
Henry Klassen |
Clinical Trial Stage Projects |
A Phase 2 Study of the Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects with Retinitis Pigmentosa |
$6,608,592 |
Cedars-Sinai Medical Center |
Clive Svendsen |
Clinical Trial Stage Projects |
Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis Pigmentosa |
$10,444,063 |
University of California, Los Angeles |
Sophie Deng |
Clinical Trial Stage Projects |
Safety and Feasibility of Cultivated Autologous Limbal Stem Cells for Limbal Stem Cell Deficiency |
$10,301,486 |
Brain Neurotherapy Bio |
Krystof Bankiewicz |
Clinical Trial Stage Projects |
A Phase 1b Safety Study for MRI guided delivery of AAV2-GDNF for the treatment of Parkinson’s disease |
$5,510,462 |
University of California, Los Angeles |
Caroline Kuo |
Therapeutic Translational Research Projects |
Ex Vivo Gene Editing of Human Hematopoietic Stem Cells for the Treatment of X-Linked Hyper-IgM Syndrome |
$4,896,628 |
City of Hope, Beckman Research Institute |
Karen Aboody |
Therapeutic Translational Research Projects |
Neural Stem cell-mediated oncolytic immunotherapy for ovarian cancer |
$2,873,262 |
University of California, Los Angeles |
Yvonne Chen |
Therapeutic Translational Research Projects |
BCMA/CS1 Bispecific CAR-T Cell Therapy to Prevent Antigen Escape in Multiple Myeloma |
$3,176,805 |
Neurona Therapeutics |
Cory Nicholas |
Therapeutic Translational Research Projects |
Development of a human stem cell-derived inhibitory neuron therapeutic for the treatment of chronic focal epilepsy |
$4,848,505 |
University of California, San Diego |
Mark Tuszynski |
Therapeutic Translational Research Projects |
Human Embryonic Stem Cell-Derived Neural Stem Cells for Severe Spinal Cord Injury (SCI) |
$6,235,897 |
Sanford Burnham Prebys Medical Discovery Institute |
Evan Snyder |
Therapeutic Translational Research Projects |
Human Neural Stem Cells (hNSCs) for neuroprotection in perinatal hypoxic-ischemic brain injury (HII)-Pre-IND-enabling Studies |
$4,963,684 |
City of Hope, Beckman Research Institute |
Saul Priceman |
Clinical Trial Stage Projects |
A Phase I Study of Chimeric Antigen Receptor Engineered Stem/Memory T Cells for the Treatment of HER2-Positive Brain Metastases |
$9,015,149 |
University of Southern California |
Mark Humayun |
Therapeutic Translational Research Projects |
PRPE-SF, polarized hESC-derived RPE Soluble Factors, as a Therapy for Early Stage Dry Age-related Macular Degeneration |
$3,733,556 |
University of California, Irvine |
Brian Cummings |
Therapeutic Translational Research Projects |
An optimized human neural stem cell line (hNSC) for the treatment of traumatic brain injury (TBI) |
$4,804,737 |
University of California, Davis |
Mehrdad Abedi |
Conference - The 2020 Alpha Stem Cell Clinic Annual Symposium |
CIRM - Leading the New Era of Living Medicines |
$60,000 |
University of California, San Diego |
Stephanie Cherqui |
Clinical Trial Stage Projects |
Phase 1/2 study for autologous human CD34+ hematopoietic stem cells ex vivo transduced with pCCL-CTNS lentiviral vector for treatment of Cystinosis. |
$11,999,944 |
University of California, San Francisco |
Peter Stock |
Clinical Trial Stage Projects |
Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Diabetes in the Intra-Muscular Site: PARADIGM |
$11,083,012 |
Aspen Neuroscience |
Andres Bratt-Leal |
Progression Award - Discovery Stage Research Projects |
Autologous therapy for Parkinson's disease: single cell RNAseq for in depth characterization of transplanted cells |
$177,579 |
University of California, San Francisco |
Mark Walters |
Late Stage Preclinical Projects |
Curing Sickle cell Disease with CRISPR-Cas9 genome editing |
$2,242,805 |
University of California, Los Angeles |
Theodore Nowicki |
Clinical Trial Stage Projects |
Genetic Modification of Stem Cells and T cells to Activate the Immune System to Target Solid Tumors |
$4,693,839 |
Rocket Pharmaceuticals, Inc. |
Kinnari Patel |
Clinical Trial Stage Projects |
LADICell |
$6,567,085 |
Cal State Univ, San Marcos |
Bianca Mothe |
Conference - Manage The Bridges Annual Meeting |
2020 and 2021 Bridges Annual Meeting |
$320,000 |
Ankasa Regenerative Therapeutics |
Ying Zhu |
Late Stage Preclinical Projects |
IND-enabling development of ART352-L, an endogenous stem cell reactivation therapy to enhance bone healing in the elderly |
$3,987,693 |
Stanford University |
Judith Shizuru |
Clinical Trial Stage Projects |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$1,113,487 |
Jasper Therapeutics, Inc. |
Wendy Pang |
Clinical Trial Stage Projects |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$2,313,398 |
University of California, Irvine |
Leslie Thompson |
Late Stage Preclinical Projects |
An hESC-derived hNSC Therapeutic for Huntington’s Disease |
$5,635,393 |
Stanford University |
Everett Meyer |
Clinical Trial Stage Projects |
Induction of Tolerance by Combinatorial Therapy w/ Donor Stem Cells and Expanded Recipient Treg cells in HLA-mismatched Kidney Transplant Recipients |
$11,955,585 |
Angiocrine Bioscience, Inc. |
Edward Kavalerchik |
Clinical Trial Stage Projects |
AB-205-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-205 |
$6,192,579 |
University of California, Davis |
Diana Farmer |
Late Stage Preclinical Projects |
Placental Mesenchymal Stem Cell Augmentation of Fetal Myelomeningocele Repair |
$5,619,643 |
Pathways to Stem Cell Science |
Victoria Fox |
Conference - Manage The SPARK Annual Meeting |
2019 SPARK Annual Meeting |
$49,915 |
University of California, San Diego |
Jonathan Lin |
Quest - Discovery Stage Research Projects |
Small Molecule Proteostasis Regulators to Treat Photoreceptor Diseases |
$1,160,648 |
Children's Hospital of Los Angeles |
Tracy Grikscheit |
Quest - Discovery Stage Research Projects |
Universal Pluripotent Liver Failure Therapy (UPLiFT) |
$1,297,512 |
Scripps Research Institute |
Stuart Lipton |
Quest - Discovery Stage Research Projects |
Drug Development for Autism Spectrum Disorder Using Human Patient iPSCs |
$1,827,576 |
Stanford University |
Philip Beachy |
Quest - Discovery Stage Research Projects |
Pluripotent stem cell-derived bladder epithelial progenitors for definitive cell replacement therapy of bladder cancer |
$1,265,436 |
University of Southern California |
Neil Segil |
Quest - Discovery Stage Research Projects |
A screen for drugs to protect against chemotherapy-induced hearing loss, using sensory hair cells derived by direct lineage reprogramming from hiPSCs |
$741,574 |
Stanford University |
Alan Cheng |
Quest - Discovery Stage Research Projects |
Modulation of the Wnt pathway to restore inner ear function |
$1,394,870 |
City of Hope, Beckman Research Institute |
Xiuli Wang |
Late Stage Preclinical Projects |
CMV-specific T cells expressing anti-HIV CAR and CMV vaccine boost as immunotherapy for HIV/AIDS |
$3,812,797 |
University of California, San Francisco |
Karin Gaensler |
Therapeutic Translational Research Projects |
Developing engineered autologous leukemia vaccines to target residual leukemic stem cells |
$4,171,728 |
University of California, Los Angeles |
Steven Schwartz |
Therapeutic Translational Research Projects |
Clinical Translation of Autologous Regenerative Cell Therapy for Blindness |
$5,068,026 |
Stanford University |
Theodore Leng |
Therapeutic Translational Research Projects |
NeuBright, a purified allogeneic cell therapy product for treatment of Dry Age-related Macular Degeneration |
$4,235,758 |
University of California, San Francisco |
Mark Walters |
Conference - The 2019 Alpha Stem Cell Clinic Annual Symposium |
2019 Alpha Stem Cell Clinic Symposium - Mending Stem Cells: The Past, Present & Future Regenerative Medicine |
$60,000 |
University of California, San Diego |
Eric Adler |
Quest - Discovery Stage Research Projects |
Genetically Modified Hematopoietic Stem Cells for the Treatment of Danon Disease |
$1,393,200 |
University of California, Los Angeles |
Lili Yang |
Quest - Discovery Stage Research Projects |
Preclinical Development of An HSC-Engineered Off-The-Shelf iNKT Cell Therapy for Cancer |
$1,404,000 |
Gladstone Institutes, J. David |
Li Gan |
Quest - Discovery Stage Research Projects |
Develop iPSC-derived microglia to treat progranulin-deficient Frontotemporal Dementia |
$1,547,157 |
Salk Institute for Biological Studies |
Ronald Evans |
Quest - Discovery Stage Research Projects |
Therapeutic immune tolerant human islet-like organoids (HILOs) for Type 1 Diabetes |
$1,637,209 |
Poseida Therapeutics, Inc. |
Devon Shedlock |
Late Stage Preclinical Projects |
Late-Stage Preclinical Study of CAR-T Memory Stem Cells Targeting PSMA (P-PSMA-101) for the Treatment of Castrate-Resistant Metastatic Prostate Cancer |
$3,992,090 |
University of California, San Francisco |
Hideho Okada |
Quest - Discovery Stage Research Projects |
Non-viral reprogramming of the endogenous TCRα locus to direct stem memory T cells against shared neoantigens in malignant gliomas |
$900,000 |
City of Hope, Beckman Research Institute |
Saul Priceman |
Quest - Discovery Stage Research Projects |
Chimeric Antigen Receptor-Engineered Stem/Memory T Cells for the Treatment of Recurrent Ovarian Cancer |
$1,381,104 |
Stanford University |
Katja Weinacht |
Quest - Discovery Stage Research Projects |
Regenerative Thymic Tissues as Curative Cell Therapy for Patients with 22q11 Deletion Syndrome |
$1,251,720 |
University of California, San Francisco |
Krystof Bankiewicz |
Late Stage Preclinical Projects |
MRI Guided Delivery of Neural Progenitor Cells Secreting GDNF for the Treatment of Parkinson's disease |
$5,811,340 |
City of Hope, Beckman Research Institute |
John Zaia |
Late Stage Preclinical Projects |
Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients |
$3,684,259 |
University of California, Los Angeles |
Steven Dubinett |
Clinical Trial Stage Projects |
A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
$10,955,315 |
MAX BioPharma, Inc. |
Farhad Parhami |
Therapeutic Translational Research Projects |
Therapeutic development of Oxy200, an oxysterol with bone anabolic and anti-resorptive properties for intervention in osteoporosis |
$1,400,000 |
Stanford University |
Bertha Chen |
Therapeutic Translational Research Projects |
Autologous iPSC-derived smooth muscle cell therapy for treatment of urinary incontinence |
$5,977,155 |
University of California, Irvine |
Magdalene Seiler |
Therapeutic Translational Research Projects |
Morphological and functional integration of stem cell derived retina organoid sheets into degenerating retina models |
$4,769,039 |
Children's Hospital of Oakland Research Institute |
Henry Erlich |
Diagnostic Translational Research Projects |
Development of a Noninvasive Prenatal Test for Beta-Hemoglobinopathies for Earlier Stem Cell Therapeutic Interventions |
$1,068,372 |
University of California, San Francisco |
Steven Mack |
Diagnostic Translational Research Projects |
Development of a Noninvasive Prenatal Test for Beta-Hemoglobinopathies for Earlier Stem Cell Therapeutic Interventions |
$653,234 |
University of California, San Francisco |
Morton Cowan |
Clinical Trial Stage Projects |
Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency Using a Lentiviral Vector to Transduce Autologous CD34 Hematopoietic Stem Cells |
$12,000,000 |
Stanford University |
Crystal Mackall |
Clinical Trial Stage Projects |
Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies |
$11,034,982 |